Clinical Trial Update: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating the efficacy and safety of JZP-258 for Idiopathic Hypersomnia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Hypersomnia

Drugs mentioned

• JZP-258

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Idiopathic Hypersomnia | Phase 3 | Status: COMPLETED | Results posted: 2021-11-24